Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 19/20 | 0.59 |
| ▸ | GSK3B | P49841 | 15/20 | 0.59 |
| ▸ | WNT1 | P04628 | 13/20 | 0.59 |
| ▸ | CLK2 | P49760 | 1/20 | 0.59 |
| ▸ | CLK3 | P49761 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23048633 | 0.92 | DYRK1A (0.57) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23916414 | 0.82 | DYRK1A (0.61) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL21214535 | 0.79 | DYRK1A (0.51) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23048703 | 0.77 | DYRK1A (0.64) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL22597057 | 0.76 | GSK3B (0.49) | DYRK1AGSK3BWNT1 | |
| SCHEMBL19517218 | 0.75 | GSK3B (1.00) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL19517385 | 0.74 | DYRK1A (1.00) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL30003768 | 0.74 | DYRK1A (1.00) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL22461726 | 0.74 | DYRK1A (0.62) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL23916189 | 0.73 | DYRK1A (0.72) | DYRK1AGSK3BWNT1CLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093970-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093970-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | DYRK1A 1006/4885GSK3B 5/4885WNT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.